Lyumjev (previously Liumjev)


insulin lispro

This medicine is authorised for use in the European Union.


Lyumjev is a medicine used to control blood glucose (sugar) levels in adults and children aged 1 year and above with diabetes. It contains the active substance insulin lispro.

This EPAR was last updated on 25/04/2023

Authorisation details

Product details
Lyumjev (previously Liumjev)
Agency product number
Active substance
insulin lispro
International non-proprietary name (INN) or common name
insulin lispro
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Eli Lilly Nederland BV
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands

Product information

18/11/2022 Lyumjev (previously Liumjev) - EMEA/H/C/005037 - II/0014

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Treatment of diabetes mellitus in adults.

Assessment history

How useful was this page?

Add your rating
2 ratings